Abemaciclib’s New Overall Survival Data in Early Breast Cancer: Findings from MonarchE trial - Video
In this short video, Prof Stephen Johnston, Consultant Medical Oncologist, Royal Marsden Hospital and Institute of Cancer ...
Some women adopted non-Jewish identities to support the resistance. For most, though, it was simply a strategy for survival – ...
Nimbus will use its AI to help identify drug candidates, while Lilly will contribute its metabolic-disease expertise to ...
Bimekizumab exhibited superior drug survival rates among patients with psoriasis who have previously stopped responding to at ...
Investor's Business Daily on MSN
Eli Lilly, IBD stock of the day, offers two entries on rumored buyout rally
Eli Lilly is Wednesday's IBD Stock Of The Day. Shares are breaking above a pair of bases as rumors swirl about a potential ...
Nurix advances CLL therapy with NX-5948 showing 83% response, 22.1-month PFS, $680M cash, and $3B risk-adjusted sales ...
Evangeline Lilly shared that a recent set of brain scans revealed she has brain damage after falling face-first in Hawaii in ...
In this week’s edition of InnovationRx, we look at a ‘holy grail’ pill for sleep apnea, Pomelo Care’s expansion, Nvidia and ...
Lionsgate has released a third and final trailer for Greenland 2: Migration , and it leans hard into the emotional weight of ...
Girl Taken is being marketed as an emotionally charged, trauma-driven thriller, as opposed to a twist-first mystery. In ...
Oncolytics also recently expanded its Scientific Advisory Board with globally recognized experts from Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center , positioning the company for ...
The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug review voucher.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results